HEPA News and Press, Hepion Pharmaceuticals Inc. From 02/09/21

EDISON, NJ / ACCESSWIRE / February 9, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver di...

NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Th...

EDISON, NJ / ACCESSWIRE / January 5, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver dis...

Calithera Biosciences (CALA) -56% as telaglenastat fails in kidney cancer study; lowers headcount.Genworth Financial (GNW) -29% after merger end-date passes.QuantumScape (QS) -18%.AeroCentury (ACY) -12%.FG Financial Group (FGF) -11%.Chindata Group Holdings (CD) -10%.PEDEVC...

Gainers: Bionano Genomics (BNGO) +82%, DermTech (DMTK) +25%, IMAC Holdings (IMAC) +20%, Gritstone Oncology (GRTS) +15%, Hepion Pharmaceuticals (HEPA) +12%.Losers: Regional Health Properties (RHE) -20%, Osmotica Pharmaceuticals (OSMT) -20%, Equ...

Penny Stocks With Big Price Targets Whether you’re looking for penny stocks to buy on Robinhood, ETrade, TD, Webull, Interactive Brokers, or other platforms, everyone has 1 goal. At least I would hope everyone has one goal, which is to make money. One of the interesting p...

Hepion Pharmaceuticals  (HEPA) announces data from its low dose cohort in its Phase 2a ‘AMBITION' clinical trial of CRV431 in NASH patients with evidence of moderate-to-severe fibrosis.This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH pat...

CRV431 Demonstrated to be Generally Safe and Well Tolerated Clinically Significant Reductions in Important Biomarkers, ALT and AST, Observed in 28 Days Study Continuing with Higher Dose EDISON, NJ / ACCESSWIRE / December 29 , 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ...

Universal Security Instruments (UUU) +293%.Technical Communications (TCCO) +214%.Koss Corporation (KOSS) +99%.Tenax Therapeutics (TENX) +80%.New Concept Energy (GBR) +58%.IRIDEX Corporation (IRIX) +23%.SOS Limited (SOS) +10% after announcing partnership with Zhonglu P&C Insuranc...

Hepion Pharmaceuticals (HEPA) announces that an independent Data Safety Monitoring Board has approved the continuation of the company's Phase 2a clinical trial for its lead asset CRV431 in NASH (non-alcoholic steatohepatitis) patients with moderate-to-severe fibrosis.The two evaluat...